Login
Companies $ADCT
$1.25 +$0.00 (0.0%) After hours
ADC Therapeutics SA logo

ADC Therapeutics SA

adctherapeutics.com

What Do They Do?

Sells ZYNLONTA, a targeted cancer medicine for relapsed or refractory large B-cell lymphoma, to healthcare providers and hospitals, and develops other antibody-drug conjugate medicines.

How Do They Make Money?

Most revenue comes from U.S. ZYNLONTA sales through wholesale distributors, with product revenue counted when the product transfers to the customer. Outside the U.S., partners provide upfront and milestone license payments and royalties; license fees may be earned at once or over time.

revenue
SegmentShareRevenue
Product revenues, net
Sold outright

90%
FY2022: 36%
License revenues
Licensed
6.2%
FY2022: 64%
Royalties
Licensed
3.5%
FY2022: 0.0%

Who Are Their Customers?

The U.S. sales team calls on healthcare providers, while wholesale distributors resell ZYNLONTA to providers and hospitals; outside the U.S., licensing partners and a joint venture handle commercialization.

Do Revenues Turn Into Profits?

No. It lost $142.6M in FY2025.

Operating income, FY2025
−149% of revenue
▲ +7% (Loss) vs FY2024 (−$130.7M, −184%)
Net income, FY2025
−175% of revenue
▲ +10% (Loss) vs FY2024 (−$157.8M, −223%)
Free cash flow, FY2025
−174% of revenue
▼ −13% (Loss) vs FY2024 (−$124.7M, −176%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +32%
vs $16.4M in Q3 FY2025
Net income
▲ +38% (Loss)
vs −$41M in Q3 FY2025
Product revenues, net share of revenue vs 95.9% in Q3 FY2025
  • Nov 9, 2026 Tanabe filed for ZYNLONTA approval in Japan and sublicensed commercialization The Japanese partner submitted an application and granted Nippon Shinyaku exclusive sublicensing rights for commercialization in Japan.

Growing. Revenue grew 2.4x in 4 years, from $33.9M in FY2021 to $81.4M in FY2025, about 24% a year.

A narrower development focus The earlier report described a broader pipeline of PBD-based candidates and plans to broaden the ADC platform. The latest report focuses resources on ZYNLONTA expansion and an exatecan-based PSMA-targeting candidate.

Revenue over time
Product revenues, net License revenues Royalties
$250M$125M$0

Who Do They Compete With?

Competes with AbbVie, Daiichi Sankyo, Genmab, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Mersana Therapeutics, Sanofi, Roche Holding, Pfizer, and Zymeworks

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support